{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-24-000099","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.715615+00:00","generated_at":"2026-05-31T05:14:07.650732+00:00","sec_items":["5.02","7.01","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aurinia restructures board: 3 directors resign, Kevin Tang appointed, CEO Greenleaf stays","bullets":["Board accepted conditional resignations of Daniel Billen, Hector MacKay-Dunn, and Brinda Balakrishnan, effective Sept 9, 2024.","CEO Peter Greenleaf remains director; Board cited exceptional circumstances for rejecting his conditional resignation.","Kevin Tang, President of Tang Capital Management, appointed as director effective Sept 12, 2024.","Board reduced from 9 to 7 members; Amended and Restated Bylaws now authorize Board to set director count."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-24-000099","json":"https://secwatch.observer/filing/0001600620-24-000099.json","markdown":"https://secwatch.observer/filing/0001600620-24-000099.md","text":"https://secwatch.observer/filing/0001600620-24-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/auph-20240909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:14:07.650732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2167e93b49","claim":"Kevin Tang was appointed as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"Effective September 12, 2024, the Board appointed Kevin Tang, President of Tang Capital Management, LLC, a life sciences-focused investment company that he founded in 2002, as member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"834000d709","claim":"Brinda Balakrishnan resigned as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fbda93d494","claim":"R. Hector MacKay-Dunn resigned as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fd0da9247e","claim":"Daniel G. Billen resigned as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}